Abstract
Background Recent several studies have showed that the nanog overexpression leads to poor prognosis in some kinds of cancer including hepatocellular carcinoma and gastrointestinal luminal cancer. However, the correlations between prognosis and clinic-pathological features and nanog overexpression in lung cancer are still not well-known. Thus, we performed a meta-analysis to evaluate the role of nanog in lung cancer. Methods An electronic retrieval for related studies was conducted in PubMed, Cochrane Library, Web of Science, EMBASE databases, Chinese CNKI, and the Chinese Wan Fang database up to May 2018. The relationships between nanog overexpression and overall survival (OS) and disease-free survival (DFS) as well as clinic-pathological features in lung cancer were investigated. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by STATA12. Results 11 studies containing 1422 patients were identified in our meta-analysis. The overexpression of nanog showed decreased OS (HR = 1.83, 95% CI = 1.49-2.25, P ≤ 0.001) and DFS (HR = 1.86, 95% CI = 1.2-2.9, P = 0.006). Moreover, overexpression of nanog was significantly related to differentiation (OR = 4.17, 95% CI = 2.17-6.43, P ≤ 0.001), lymph node metastasis (OR = 1.76, 95% CI = 1.06-2.91, P = 0.028) and tumor size (OR = 1.93, 95% CI = 1.17-3.20, P = 0.010), and no correlation with T stage, TNM, stage, and gender. Conclusions Our results suggested that nanog overexpression, a hazard factor of differentiation, lymph node metastasis, and tumor size, may predicate decreased OS and DFS for lung cancer.
Highlights
Lung cancer is ranked at the first in both incidence and mortality worldwide [1, 2]
Nanog overexpression was not correlated with T stage (T3 - T4 versus T1 - T2: odds ratios (ORs) = 0.85, 95% confidence intervals (CIs) = 0.57-1.34, P = 0.541, fixed effect, Figure 4(d)), TNM stage (III + IV versus I + II: OR = 1.22, 95% CI = 0.88-1.68, P = 0.227, fixed effect, Figure 4(e)), and gender (man versus women: OR = 1.19, 95% CI = 0.871.62, P = 0.287, fixed effect, Figure 4(f)). These results revealed that nanog overexpression conferred poor differentiation and undifferentiation, lymph node metastasis, and tumor size
It is emergency for us to explore the new mechanism of metastasis and recurrence and look for related prognostic markers and targets of therapeutic interventions to improve the prognosis for lung cancer
Summary
Lung cancer is ranked at the first in both incidence and mortality worldwide [1, 2]. Significant progress has been made in the diagnosis and treatment of lung cancer in recent years, the etiology of lung cancer is still relatively complicated, and the therapeutic effectiveness is still not satisfactory in Europe and USA [3]. Radical surgery is the main treatment regimen for early lung cancer and these patients have relatively high overall survival (OS) and diseasefree survival (DFS). The relationships between nanog overexpression and overall survival (OS) and disease-free survival (DFS) as well as clinic-pathological features in lung cancer were investigated. Overexpression of nanog was significantly related to differentiation (OR = 4.17, 95% CI = 2.17-6.43, P ≤ 0.001), lymph node metastasis (OR = 1.76, 95% CI = 1.06-2.91, P = 0.028) and tumor size (OR = 1.93, 95% CI = 1.17-3.20, P = 0.010), and no correlation with T stage, TNM, stage, and gender. Our results suggested that nanog overexpression, a hazard factor of differentiation, lymph node metastasis, and tumor size, may predicate decreased OS and DFS for lung cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
